These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91 related articles for article (PubMed ID: 2024552)
21. Toxicological study on a new nitrosourea derivative, 1-(2-chloroethyl)-3-isobutyl-3-(beta-maltosyl)-1-nitrosourea. Fujimoto S; Ogawa M Jpn J Cancer Res; 1985 Jul; 76(7):651-6. PubMed ID: 3928562 [TBL] [Abstract][Full Text] [Related]
22. [Pharmacological studies on MCNU: a new antitumor agent]. Sekido S; Hosono J; Hiratsuka K; Araki T; Iwasaki M Nihon Yakurigaku Zasshi; 1988 Aug; 92(2):69-96. PubMed ID: 3224900 [TBL] [Abstract][Full Text] [Related]
23. [A case of myelofibrosis that developed polycythemia vera following treatment with ranimustine and then acute myelogenous leukemia (M0)]. Harashima S; Okamura T; Umeno M; Takaki K Rinsho Ketsueki; 1996 Aug; 37(8):713-8. PubMed ID: 8827883 [TBL] [Abstract][Full Text] [Related]
24. Review of experimental studies on nitrosourea derivatives in Japan. Tsukagoshi S Recent Results Cancer Res; 1980; 70():107-17. PubMed ID: 7355242 [TBL] [Abstract][Full Text] [Related]
26. [Clinical trial of MCNU for malignant brain tumors]. Harada K; Okamoto H; Fujioka Y; Uozumi T; Kiya K; Kitaoka T; Goishi A; Sasaki U; Shima T; Inagawa T Gan To Kagaku Ryoho; 1985 Jul; 12(7):1423-31. PubMed ID: 2990350 [TBL] [Abstract][Full Text] [Related]
27. [Successful treatment by ranimustine (MCNU) of a patient with B-cell prolymphocytic leukemia (B-PLL)]. Wake A; Yamasaki Y; Ogawa R; Mori N; Nagata K; Nakata K; Misago M; Izumi Y; Fujita K; Oda S Rinsho Ketsueki; 1993 Nov; 34(11):1464-9. PubMed ID: 8254909 [TBL] [Abstract][Full Text] [Related]
28. Phase I trial of a new nitrosourea, CGP 6809, given every 2 weeks. Creaven PJ; Cowens JW; Huben R; Petrelli N; Karakousis C; Traynor D Cancer Chemother Pharmacol; 1989; 23(4):266-7. PubMed ID: 2924383 [TBL] [Abstract][Full Text] [Related]
29. [Phase II study on oral administration of MCNU (ranomustine) tablet. Hanshin Cooperative Study Group on Hematological Disorders]. Kanamaru A; Nagai K; Masaoka T; Shibata H; Kitani T; Taniguchi N; Horiuchi A; Tsubaki K; Kawagoe H; Hirata M Gan To Kagaku Ryoho; 1986 May; 13(5):1915-20. PubMed ID: 3458432 [TBL] [Abstract][Full Text] [Related]
30. Recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2) immunotherapy with ranimustine chemotherapy and concurrent radiation therapy for malignant astrocytomas. Fukushima T; Yamamoto M; Oshiro S; Tsugu H; Hirakawa K; Soma G Anticancer Res; 2003; 23(6a):4473-81. PubMed ID: 14666736 [TBL] [Abstract][Full Text] [Related]
31. [Effect of MCNU on brain tumors. Part II: Clinical experience with MCNU on malignant brain tumors]. Wakabayashi T; Yoshida J; Kito A; Inoue I; Kobayashi T; Kageyama N Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2729-37. PubMed ID: 6095764 [TBL] [Abstract][Full Text] [Related]
33. [Successful treatment of splenomegaly and anemia by VP therapy in idiopathic myelofibrosis complicated with acromegaly: a case report]. Imai Y; Akiyama N; Hanazono Y; Inamori K; Mitani K; Hirai H; Nagai R; Yazaki Y Rinsho Ketsueki; 1995 Oct; 36(10):1233-6. PubMed ID: 8531337 [TBL] [Abstract][Full Text] [Related]
34. Delivery of a novel nitrosourea, MCNU, to the brain tissue in glioma-bearing rats. Intracarotid versus intravenous infusion. Hodozuka A; Sako K; Nakai H; Tomabechi M; Suzuki N; Yonemasu Y J Neurooncol; 1993 Jan; 15(1):79-86. PubMed ID: 8455066 [TBL] [Abstract][Full Text] [Related]
35. [Study on three patients with malignant glioma showing tumor reduction during maintenance therapy with MCNU]. Kiya K; Uozumi T; Kurisu K; Mikami T; Sugiyama K; Monden S; Maeda H; Matsuoka T; Matsuda Y; Harada K Gan To Kagaku Ryoho; 1993 Jun; 20(8):1083-6. PubMed ID: 8512339 [TBL] [Abstract][Full Text] [Related]
36. Phase I study of GANU and MCNU. Ogawa M Cancer Treat Rev; 1980 Dec; 7(4):197-203. PubMed ID: 6452200 [No Abstract] [Full Text] [Related]
37. [Therapeutic effect of ranimustine(MCNU) on myeloproliferative disorder and chronic myelomonocytic leukemia]. Maeda S; Okabe M; Kurosawa M; Kunieda Y; Imamura M; Morioka M; Sakurada K; Miyazaki T; Sukegawa M Gan To Kagaku Ryoho; 1991 Feb; 18(2):251-8. PubMed ID: 1992919 [TBL] [Abstract][Full Text] [Related]
38. [Experimental studies on oral administration of nitrosourea anti-tumor agent, MCNU]. Sekido S; Ninomiya K; Araki T; Ueno M; Kinbara M Gan To Kagaku Ryoho; 1984 Jul; 11(7):1492-500. PubMed ID: 6234861 [TBL] [Abstract][Full Text] [Related]
39. Therapeutic and diabetogenic potential of two newly synthesized nitrosoureido sugars. Bernacki RJ; Wilson GL; Mossman BT; Angelino N; Kanter PM; Korytnyk W Cancer Res; 1985 Feb; 45(2):695-702. PubMed ID: 3881170 [TBL] [Abstract][Full Text] [Related]
40. Efficacy of post operative adjuvant therapy with human interferon beta, MCNU and radiation (IMR) for malignant glioma: comparison among three protocols. Hatano N; Wakabayashi T; Kajita Y; Mizuno M; Ohno T; Nakayashiki N; Takemura A; Yoshida J Acta Neurochir (Wien); 2000; 142(6):633-8; discussion 639. PubMed ID: 10949437 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]